A Danish nationwide cohort study also reported a lower risk of corticosteroid use and hospitalization in IBD patients with DM2 undergoing GLP-1 RAs rather than other antidiabetic treatments (98). This evidence concerns the gene GLP1R and inflammatory bowel disease.